Abzena has introduced an accelerated cell line development program to IND, which it says reduces the timeline from stable pool to GMP down to 14 months. The timeline is achieved by use of single project team with experienced leadership, overlapping of operational activities, internal technology transfer within Abzena, proprietary technologies and scalable single use bioreactors.   Abzena builds on a track record of 10 biotherapeutics currently in integrated IND phase of development or early clin...